SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The fina...
Read moreNina Capital, an emerging specialist venture capital firm, today announced its second fund, started last fall, eclipsed its target size of EUR40 million in just four months. The fund will be used to c...
Read moreAlrededor de 40 empresas y agentes del sector biotecnológico de Galicia, Cataluña, País Vasco, Asturias, Madrid, Aragón, Comunidad Valenciana y Portugal participaron ayer en Health BioMatch, un en...
Read moreLess than one month after the presentation of the 2021 BioRegion of Catalonia Report celebrating another year of record funding, SpliceBio closed one of the biggest rounds of funding in the life scien...
Read moreAfter a very active 2021, closing an oversubscribed €216M fund, 3 NASDAQ IPOs, and Sanifit’s landmark acquisition by Vifor Pharma, Ysios Capital is now focused on managing its portfolio companies ...
Read moreMedibiofarma ha cerrado una ronda de financiación de 1,2 millones de euros, con el apoyo financiero de su equipo promotor y otros socios de contrastada experiencia en el ámbito de la salud y la tecn...
Read moreIntegra Therapeutics, a biotechnology company that creates next generation gene writing tools, has closed an additional €1.5-million investment from venture capital firm Columbus Venture Partners. T...
Read moreEl líder global en terapias de salud digital Sidekick Health (www.sidekickhealth.com) anuncia hoy el cierre de una ronda de financiación Serie B de $55 millones. La ronda ha sido liderada por la fir...
Read moreAs we already know, public funding is not enough to cover the entire life cycle of a company in the health sector. In fact, it is becoming increasingly common for public funding sources to contain in ...
Read moreThanks to a new Proof of Concept Grant granted today by the European Research Council (ERC), CRG researchers led by Dr. Luis Serrano will explore new methods that improve the therapeutic effectiveness...
Read moreThe round was co-led by Columbus Venture Partners and Caixa Capital Risc. Dr. Damià Tormo, representing Columbus Venture Partners, has joined Minoryx’s Board of Directors. CDTI, through its Innvier...
Read moreMineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-H...
Read more